Abstract 1922P
Background
Advanced angiosarcoma comprises an aggressive sarcoma subset that exhibits poor prognosis and short-term duration of responses. Series treated with anthracyclines or taxanes reported an mPFS that ranged from 2.7 to 3.7 m. A trial with sorafenib reported a mPFS of 1.8 and 3.8 m, 6-m-PFSr of 25% and 31% (9m-PFSr of 0 and 3.8%), ORR of 15 and 13% and mOS of 9 and 12 m, for superficial and visceral cohorts respectively. As IMMUNOSARC I master-trial exploring sunitinib (S) plus nivolumab (N) in sarcoma detected signal of activity in angiosarcoma patients, a specific cohort of vascular sarcomas was designed as phase II trial in IMMUNOSARC II (NCT03277924).
Methods
Advanced, recently progressing, measurable and centrally reviewed vascular sarcomas (angiosarcoma, intimal sarcoma and epithelioid hemangioendothelioma) were enrolled and treated with S: 37.5 mg/d in first 14 days, then continued with 25 mg/d, along with N 240 mg every 2 weeks up to progression or intolerance. Imaging tests were assessed every 8 weeks. The main endpoint was 6m-PFSr, and the statistical assumptions were obtaining a 6m-PFSr in at least 11 patients out of 23 patients, with H0=30% and H1=60% (α 0.05; β 0.10).
Results
Patients with angiosarcoma (17), EHE (6) and intimal sarcomas (3) were accrued from Oct. 2019 to Apr. 2023 in 8 centers from Spain, Italy and UK. Patients had a median age of 60 y (25-82), F=20/M=6 distribution and a median of previous lines of 2 (0-5). Median follow-up was 24 m (5.9-42.1). The 6m-PFSr was 45% (23-66) for 23 evaluable patients. Considering angiosarcoma patients, there were 5 (33%) PR, 7 (47%) SD and 3 (20%) PD out of 15 evaluable patients. The mPFS was 3.93 m and the 6m-PFSr was 36% (11-61). The mOS was 15.73 m (1.83-29.64). End-of-treatment reasons were PD 71%, toxicity 22% and doctor decision 7%. Most common grade 3-4 TREAEs were neutropenia (11.8%) and asthenia (11.8%).
Conclusions
S and N combination has demonstrated to be active in advanced vascular sarcomas. This activity favorably compares with that previously reported for sorafenib activity. Even though the outcome did not reach the H1, antiangiogenics and PD1 inhibitors deserve to be explored, maybe with other combinations, in vascular sarcomas.
Clinical trial identification
NCT03277924.
Editorial acknowledgement
Legal entity responsible for the study
Spanish Group for Research on Sarcoma (GEIS).
Funding
Pfizer and BMS.
Disclosure
J. Martinez Trufero: Financial Interests, Personal, Advisory Board, Advisory Board meeting: PharmaMar, Eisai; Financial Interests, Personal, Invited Speaker: Roche, Eisai, Merck, Medicamenta, MSD, Ipsen; Financial Interests, Personal, Advisory Board, Advisory Board Meeting: GSK, Deciphera, Boehringer Ingelheim, Eisai; Financial Interests, Institutional, Local PI, Clinical trial: RAIN Therapeutics, Blueprint, Lilly, Kariopharm Therapeutics, Syneos Health, Boehringer Ingelheim, Ayala Pharmaceuticals, SynOx Therapeutics; Non-Financial Interests, Member of Board of Directors, Spanish group of Sarcoma Research: GEIS Group; Non-Financial Interests, Member of Board of Directors, Spanish Group of Head and Neck cancer Research: TTCC Group. S. Strauss: Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board, medical advisor: Ceridwen Oncology. S. Stacchiotti: Financial Interests, Personal, Advisory Board: Bayer, Bavarian Nordic, Daiichi Sankyo, Novartis, Ikena, Astex Pharmaceuticals, Rain Therapeutics; Financial Interests, Personal, Invited Speaker: GSK, PharmaMar, Aadi; Financial Interests, Personal, Advisory Board, Advisory board meeting: Agenus; Financial Interests, Personal, Advisory Board, Advisory board meetings: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker, Lectures: Gentili; Financial Interests, Personal, Advisory Board, Advisory board: Servier; Financial Interests, Institutional, Local PI: Advenchen, Deciphera, Epizyme, Daiichi Sankyo, GSK, Karyopharm, PharmaMar, SpringWorks, Hutchison MediPharma International Inc, Inhibrix; Financial Interests, Institutional, Coordinating PI: Bayer; Financial Interests, Institutional, Funding: Blueprint, Novartis; Non-Financial Interests, Member of Board of Directors, Secretary: Connective Tissue Oncology; Non-Financial Interests, Advisory Role: Chordoma Foundation, Epithelioid Haemangiondothelioma Foundation , Desmoid Foundation , Epithelioid Hemangioendothelioma (EHE) Rare Cancer Charity (UK); Non-Financial Interests, Other, Secretary: EORTC soft tissue and bone sarcoma group; Non-Financial Interests, Leadership Role, President: Italian Sarcoma Group. D. Da Silva Moura: Financial Interests, Personal, Other, Travel: Pfizer. J. Martin-Broto: Financial Interests, Personal, Advisory Board, Honoraria: Lilly, PharmaMar, Eisai, Bayer, Roche, Boehringer Ingelheim, Amgen; Financial Interests, Personal, Invited Speaker: PharmaMar; Financial Interests, Personal, Advisory Board, Speaker: Tecnofarma, Asofarma; Financial Interests, Institutional, Coordinating PI: PharmaMar, Eisai, Novartis, IMMIX Biopharma, Lixte, Karyopharm, Bayer, Celgene, Pfizer, BMS, Lilly; Financial Interests, Institutional, Local PI: Blueprint, Deciphera, Nektar, Forma, Amgen, Daiichi Sankyo, Arog, Adaptimmune, GSK, Ran Therapeutics, Inhibrx, Ayala Pharmaceuticals, Philogen, Cebiotex, PTC Therapeutics, Inc. and SpringWorks therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
1950P - A single-arm, phase II clinical trial of neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma
Presenter: Yong Chen
Session: Poster session 15
1951P - Propranolol monotherapy in angiosarcoma: A window-of-opportunity study (PropAngio)
Presenter: Alaa Embaby
Session: Poster session 15
1952P - Efficacy and safety of utidelone in previously treated patients with advanced or metastatic soft tissue sarcomas (HX-SARC02): A prospective, single-arm, phase II study
Presenter: yu jiang
Session: Poster session 15
1953P - Prognostic value of pretreatment inflammatory markers and other clinicopathological factors for early recurrence in soft tissue sarcoma
Presenter: Pia Van Der Laan
Session: Poster session 15
1954P - The risk of second primary gastrointestinal tract GIT malignancy after primary retroperitoneal liposarcoma
Presenter: Bushra Alshaikh
Session: Poster session 15
1955P - Distinguishing lipomas from atypical lipomatous tumors/well differentiated liposarcomas in histology slides using deep learning
Presenter: Marie karanian
Session: Poster session 15
1956P - Neoadjuvant chemoradiotherapy in locally advanced soft tissue sarcoma: NASAR prospective study
Presenter: Jeronimo Martinez-Garcia
Session: Poster session 15
1957P - Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)
Presenter: Rashmi Chugh
Session: Poster session 15
1958P - Head and neck soft tissue sarcoma: Evaluation of the 8th AJCC as a prognostic tool for patients treated with curative intent in a multidisciplinary cancer center
Presenter: Giulia Zanetta
Session: Poster session 15
1959P - Clinicopathological features and survival analysis of orbital rhabdomyosarcoma
Presenter: Fatma Elawady
Session: Poster session 15